rituximabhoz
Rituximab is a monoclonal antibody used primarily in the treatment of certain types of cancer and autoimmune diseases. It is produced by genetically engineering a mouse cell line to produce human antibodies against the CD20 protein, which is found on the surface of B cells. CD20 is a protein that is expressed on the surface of mature B cells and is involved in their activation and proliferation.
Rituximab works by binding to the CD20 protein on the surface of B cells, leading to the
Rituximab is approved for the treatment of several conditions, including:
* Chronic lymphocytic leukemia (CLL)
* Certain types of non-Hodgkin lymphoma
* Systemic lupus erythematosus
Rituximab is typically administered intravenously and is well-tolerated by most patients. However, it can cause side
Rituximab is generally considered to be an effective and well-tolerated treatment option for many patients with